NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

RecruitingN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Metastatic Castration Resistant Prostate Cancer

Countries: Italy

This is a local prospective, multicenter, long-term, non-interventional study using primary data collection to describe the routine clinical practice of patients with mCRPC treated with lutetium (177Lu) vipivotide tetraxetan. The observation period will be from date of start of treatment up to a maximum of 18 months after end of treatment.

Eligibility overview

Sex: MALE

Age: 18 Years to 99 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

1. Adult patients diagnosed with mCRPC eligible for and prescribed with lutetium (177Lu) vipivotide tetraxetan by the treating physician (Multidisciplinary Team).
2. ≥ 18 years old at the time of enrollment.
3. Written informed consent must be obtained to participate to this study

In addition to the above-listed criteria, no other inclusion/exclusion criteria exist other than the requirements stated in the local Summary of Product Characteristics (SmPC) and in the "Scheda di Monitoraggio AIFA", e.g., contraindications.

Locations (34)

Alessandria, AL, Italy
Asti, AT, Italy
Bergamo, BG, Italy
Brescia, BS, Italy
Catania, CT, Italy
Meldola, FC, Italy
Cona, FE, Italy
Foggia, FG, Italy
Florence, FI, Italy
Genova, GE, Italy
Genova, GE, Italy
Latina, LT, Italy
Province of Macerata, MC, Italy
Milan, MI, Italy
Milan, MI, Italy
Rozzano, MI, Italy
Palermo, PA, Italy
Padova, PD, Italy
Perugia, PG, Italy
Pisa, PI, Italy
Aviano, PN, Italy
Rionero in Vulture, PZ, Italy
Reggio Emilia, RE, Italy
Roma, RM, Italy
Roma, RM, Italy
Roma, RM, Italy
Roma, RM, Italy
La Spezia, SP, Italy
Taranto, TA, Italy
Torino, TO, Italy
+ 4 more on CT.gov